Bayer submits its new hemophilia drug for EU scrutiny; More turmoil for Sanofi;

@FierceBiotech: Does the 'sharing economy' have a place in biotech? More | Follow @FierceBiotech

@JohnCFierce: $GSK news blew away the rest of the yr's top 10 reports in terms of readers. And it was all industry/investors. Story | Follow @JohnCFierce

@DamianFierce: Sorting through $PFE for $BMY tweets is like a survey course in the epidemiology of bio Twitter BS. Highly recommended. | Follow @DamianFierce

> As promised, Bayer has filed a European application for BAY 81-8973, a new hemophilia A treatment designed to improve upon the company's own Kogenate. Bayer plans to submit filings in other countries in the coming months. News

> Sanofi ($SNY) revealed that the head of its diabetes business resigned just weeks before the company unveiled flat sales projections for the business, inviting more scrutiny on a drugmaker working to move on from a high-profile CEO firing and fight new allegations of paying kickbacks to physicians. More

Medical Device News

@FierceMedDev: Welch Allyn partners with LKC to distribute novel diabetic retinopathy device. Story | Follow @FierceMedDev

@EmilyWFierce: Covidien loses battle in patent war with J&J as top U.S. patent court throws out $176M award. More | Follow @EmilyWFierce

> Welch Allyn partners with LKC to distribute novel diabetic retinopathy device. News

> Covidien loses battle in patent war with J&J as top U.S. patent court throws out $176M award. More

> Congress looks to deflate Medicare coverage of penis pumps. Story

Pharma News

@FiercePharma: Sanofi Chairman says French tax burden a killer for attracting execs. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Sanofi, Viehbacher accused of kickback scheme in whistleblower suit. Article | Follow @EricPFierce

@CarlyHFierce: Reckitt CEO, nearing spinoff, thinks he can outdo Big Pharma in consumer health. Story | Follow @CarlyHFierce

> GSK changes its tune, plans to hold on to aging drug portfolio. More

> More turmoil in top ranks of Sanofi's diabetes business. News

> Reckitt CEO, nearing spinoff, thinks he can outdo Big Pharma in consumer health. Story

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.